

FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6







FIG. 7

VRDN-2700 NHP Serum Concentration
Intravenous InfusionVRDN-2700 NHP Serum Concentration
Subcutaneous Infusion

ROA	Dose (mg/kg)	C_{max} (µg/mL)	$AUC_{0-\infty}$ (µg*day/mL)	$t_{1/2}$ (Day)	Cl^* (mL/day/kg)
IV	2	57.7 ± 7.19	243 ± 45.8	5.87 ± 1.19	8.43 ± 1.55
	10	232 ± 3.27	2300 ± 312	14.4 ± 4.07	4.40 ± 0.570
	50	1230 ± 190	8670 ± 2840	9.23 ± 1.93	6.15 ± 1.76
SC	2	11.2 ± 3.34	98.6 ± 21.9	6.21 ± 2.25	20.9 ± 4.32
	10	68.8 ± 11.0	1420 ± 62.4	12.6 ± 1.87	7.04 ± 0.307

FIG. 8



Compound	Dose and ROA	AUC _{inf} (µg*day/mL)	Relative Exposure	t _{1/2}
VRDN-2700 (YTE)	10 mg/kg, IV	2300 ± 312	2.9X	14.4 ± 4.07
VRDN-2700 (YTE)	10 mg/kg, SC	1420 ± 62.4	1.8X	12.6 ± 1.87
Teprotumumab	10 mg/kg, IV	779 ± 79.4	1.0X	6.35 ± 0.322